Soluble SARS‐CoV‐2 RBD and human ACE2 peptidase domain produced in DrosophilaS2 cells show functions evoking virus–cell interface

Abstract

AbstractThe interaction between the receptor‐binding domain (RBD) of the spike glycoprotein of SARS‐CoV‐2 and the peptidase domain of the human angiotensin‐converting enzyme 2 (ACE2) allows the first specific contact at the virus–cell interface making it the main target of neutralizing antibodies. Here, we show a unique and cost‐effective protocol using Drosophila S2 cells to produce both RBD and soluble human ACE2 peptidase domain (shACE2) as thermostable proteins, purified via Strep‐tag with yields >40 mg L−1 in a laboratory scale. Furthermore, we demonstrate its binding with KD values in the lower nanomolar range (independently of Strep‐tag removal) and its capability to be blocked by serum antibodies in a competition ELISA with Strep‐Tactin‐HRP as a proof‐of‐concept. In addition, we assess the capacity of RBD to bind native dimeric ACE2 overexpressed in human cells and its antigen properties with specific serum antibodies. Finally, for completeness, we analyzed RBD microheterogeneity associated with glycosylation and negative charges, with negligible effect on binding either with antibodies or shACE2. Our system represents an accessible and reliable tool for designing in‐house surrogate virus neutralization tests (sVNTs), enabling the rapid characterization of neutralizing humoral responses elicited against vaccines or infection, especially in the absence of facilities to conduct virus neutralization tests. Moreover, our biophysical and biochemical characterization of RBD and shACE2 produced in S2 cells lays the groundwork for adapting to different variants of concern (VOCs) to study humoral responses elicited against different VOCs and vaccine formulations.